Abstract
On measuring the percentage of QT correction (QTc) interval prolongation, the pharmacokinetic and pharmacodynamic profiles of 7-(4-chlorbenzyl)-7,8,13,13 a-tetrahydroberberine chloride (CPU 86017) were analysed by combined pharmacokinetic and pharmacodynamic model after iv two doses in dogs. The plasma concentration-time profiles of CPU 86017 can be described by a two compartment open model. And the relationship between effect and effect compartment concentration of CPU 86017 can be represented by the Sigmoid model. The pharmacokinetic and pharmacodynamic properties were dose-independent in the dose ranges used in the experiment.
| Original language | English |
|---|---|
| Pages (from-to) | 72-75 |
| Number of pages | 4 |
| Journal | Chinese Journal of Pharmacology and Toxicology |
| Volume | 14 |
| Issue number | 1 |
| State | Published - 2000 |
| Externally published | Yes |
Keywords
- 7-(4-Chlorbenzyl)-7,8,13,13 a-tetrahydroberberine chloride
- Combined pharmacokinetic-pharmacodynamic model
- Pharmacodynamics
- Pharmacokinetics
Fingerprint
Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of 7-(4-chlorbenzyl)-7,8,13,13 a-tetrahydroberberine chloride in dogs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver